MindBio Therapeutics (XCNQ:MBIO) EV-to-EBIT : -3.74 (As of Jun. 14, 2024)

View and export this data going back to 2023. Start your Free Trial

What is MindBio Therapeutics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, MindBio Therapeutics's Enterprise Value is C$10.39 Mil. MindBio Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was C$-2.78 Mil. Therefore, MindBio Therapeutics's EV-to-EBIT for today is -3.74.

The historical rank and industry rank for MindBio Therapeutics's EV-to-EBIT or its related term are showing as below:

XCNQ:MBIO' s EV-to-EBIT Range Over the Past 10 Years
Min: -4.64 Med: -3.92 Max: -2.25
Current: -3.74

During the past 3 years, the highest EV-to-EBIT of MindBio Therapeutics was -2.25. The lowest was -4.64. And the median was -3.92.

XCNQ:MBIO's EV-to-EBIT is ranked worse than
100% of 425 companies
in the Biotechnology industry
Industry Median: 9.71 vs XCNQ:MBIO: -3.74

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. MindBio Therapeutics's Enterprise Value for the quarter that ended in Mar. 2024 was C$11.54 Mil. MindBio Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was C$-2.78 Mil. MindBio Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -24.06%.

MindBio Therapeutics EV-to-EBIT Historical Data

The historical data trend for MindBio Therapeutics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MindBio Therapeutics EV-to-EBIT Chart

MindBio Therapeutics Annual Data

Trend

Jun21

Jun22

Jun23

EV-to-EBIT

-3.92

MindBio Therapeutics Quarterly Data
	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-EBIT	Get a 7-Day Free Trial					-	-3.92	-2.93	-2.47	-4.16

Competitive Comparison of MindBio Therapeutics's EV-to-EBIT

For the Biotechnology subindustry, MindBio Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MindBio Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MindBio Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where MindBio Therapeutics's EV-to-EBIT falls into.

MindBio Therapeutics EV-to-EBIT Calculation

MindBio Therapeutics's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	10.385	/	-2.777
	=	-3.74

MindBio Therapeutics's current Enterprise Value is C$10.39 Mil.
MindBio Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-2.78 Mil.

MindBio Therapeutics (XCNQ:MBIO) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

MindBio Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 )	=	EBIT	/	Enterprise Value (Q: Mar. 2024 )
	=	-2.777	/	11.541585
	=	-24.06 %

MindBio Therapeutics's Enterprise Value for the quarter that ended in Mar. 2024 was C$11.54 Mil.
MindBio Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-2.78 Mil.

MindBio Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of MindBio Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

MindBio Therapeutics (XCNQ:MBIO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MindBio Therapeutics Corp (XCNQ:MBIO) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

WF6:Germany

Address

91-97 William Street, Level 4, Melbourne, VIC, AUS, 3000

Website

https://www.mindbiotherapeutics.com

MindBio Therapeutics Corp is pioneering clinical studies into the microdosing of psychedelic medicines to treat a range of medical conditions such as depression, anxiety, PTSD, panic disorder, chronic pain and opiate addictions. Its clinical trials microdosing of psychedelic medicines provide hope for sufferers of mental health conditions with new emerging treatment alternatives. The company invests in clinical research to discover potential new treatment options and aims to create novel medicines and treatment regimes from breakthrough microdosing studies. Geographically, the activities of the company takes place in Australia.